Connect with us

Technology

Fusion Biopsy Market is expected to generate a revenue of USD 1448.15 Million by 2032, Globally, at 8.9% CAGR: Verified Market Research®

Published

on

Verified Market Research®, a leading provider of business intelligence and market analysis is thrilled to announce the release of its comprehensive and authoritative report on the Fusion Biopsy Market. This in-depth study provides industry leaders, medical device manufacturers, healthcare providers, and investors with critical insights into the evolving landscape of fusion biopsy technologies.

LEWES, Del., March 5, 2025 /PRNewswire/ — The Global Fusion Biopsy Market Size is projected to grow at a CAGR of 8.9% from 2025 to 2032, according to a new report published by Verified Market Research®. The report reveals that the market was valued at USD 732.13 Million in 2024 and is expected to reach USD 1448.15 Million by the end of the forecast period.

The Fusion Biopsy Market is witnessing rapid growth, driven by increasing adoption of precision diagnostic techniques for prostate cancer and other malignancies. Fusion biopsy, which combines MRI and ultrasound imaging, has emerged as a game-changer in early cancer detection and treatment planning. The report delves into market dynamics, including technological advancements, regulatory updates, and competitive strategies shaping the industry.

Key Highlights of the Market Report:

Market Size & Growth Projections – Detailed analysis of the current market valuation, CAGR, and forecasted growth potential through 2032.Technological Innovations – Insights into the latest advancements in MRI-ultrasound fusion biopsy techniques, AI-powered imaging, and real-time navigation systems.Competitive Landscape – Profiles of key players, including mergers, acquisitions, and strategic partnerships that are redefining the market.Regional Analysis – Market trends and investment opportunities across North America, Europe, Asia-Pacific, and other emerging regions.End-User Insights – Adoption trends across hospitals, diagnostic centers, and research institutions.

Why This Report Matters?

With the increasing burden of cancer cases worldwide, precision diagnostics are more crucial than ever. Industry stakeholders seeking data-driven insights on investment opportunities, emerging technologies, and strategic positioning will find this report invaluable.

For more information or to purchase the report, please contact us at: https://www.verifiedmarketresearch.com/download-sample?rid=480739

Browse in-depth TOC on “Global Fusion Biopsy Market Size

202 – Pages
126 – Tables
37 – Figures

Report Scope

REPORT ATTRIBUTES

DETAILS

STUDY PERIOD

2021-2032

BASE YEAR

2024

FORECAST PERIOD

2025-2032

HISTORICAL PERIOD

2021-2023

UNIT

Value (USD Million)

KEY COMPANIES PROFILED

Eigen, Koninklijke Philips N.V., Hitachi Ltd., Focal Healthcare, MedCom, ESAOTE SPA, KOELIS, BK Medical Holding Company Inc., Biobot Surgical Pte Ltd, Exact Imaging, and UC-Care Medical Systems Ltd.

SEGMENTS COVERED

Biopsy Route, Product, End User, And Geography.

CUSTOMIZATION SCOPE

Free report customization (equivalent to up to 4 analyst working days) with purchase. Addition or alteration to country, regional & segment scope

Global Fusion Biopsy Market Overview

Key Market Drivers

Rising Prevalence of Prostate Cancer and Need for Early Diagnosis: The rising global prevalence of prostate cancer significantly propels the Fusion Biopsy Market. Conventional biopsy techniques frequently result in false negatives, postponing essential therapies. Fusion biopsy, integrating MRI and ultrasound, improves precision and early diagnosis, establishing it as the preferred method for urologists and oncologists. As healthcare providers emphasize precision diagnostics, the need for fusion biopsy systems is anticipated to increase, propelling market expansion.

Technological Advancements in Imaging and AI Integration: The advancement of MRI-ultrasound fusion biopsy technology, enhanced by artificial intelligence and real-time imaging, is revolutionizing cancer diagnoses. AI-driven automation enhances lesion diagnosis and biopsy targeting, minimizing mistakes and increasing productivity. The Fusion Biopsy Market is experiencing swift adoption in hospitals and diagnostic centers as manufacturers invest in advanced imaging systems. Organizations utilizing AI-driven biopsy advancements will acquire a significant competitive advantage.

Increasing Investments and Favorable Regulatory Approvals: Government entities and private investors are significantly financing precision diagnostic solutions, hence generating development prospects in the Fusion Biopsy Market. Beneficial FDA approvals and efficient regulatory frameworks are accelerating product introductions and promoting innovation. Increasing healthcare expenditures and reimbursement policies favoring sophisticated biopsy treatments are enhancing market penetration. Enterprises that use regulatory changes will experience substantial revenue growth.

To Purchase a Comprehensive Report Analysis: https://www.verifiedmarketresearch.com/select-licence?rid=480739

Market Restraints Hindering the Market Growth

High Cost of Fusion Biopsy Systems and Procedures: Notwithstanding its clinical benefits, the Fusion Biopsy Market encounters obstacles owing to the substantial expense of MRI-ultrasound fusion biopsy devices. Advanced imaging technology and AI-driven biopsy instruments necessitate significant investment, constraining adoption by small and medium-sized healthcare institutions. Cost-sensitive markets, especially in emerging areas, face challenges with affordability, hindering widespread implementation and impeding market growth.

Limited Access to Skilled Radiologists and Urologists: The efficacy of fusion biopsy is contingent upon the proficiency of radiologists and urologists skilled in MRI-ultrasound-guided techniques. A deficiency of trained professionals, particularly in emerging regions, is constraining market expansion. Healthcare facilities encounter difficulties in adopting and optimizing fusion biopsy technologies without enough training. Mitigating this deficiency through educational and certification initiatives is essential for fostering enduring adoption and maintaining growth in the Fusion Biopsy Market.

Stringent Regulatory Requirements and Approval Delays: Despite the rise in regulatory approvals, rigorous compliance mandates and protracted approval procedures present obstacles for new market entrants. The Fusion Biopsy Market has intricate clinical validation procedures, hindering product commercialization. Companies must manage changing rules, which can impede innovation and delay market entry. Organizations that strategically adhere to compliance requirements will be more equipped to navigate these challenges and foster continuous growth.

Geographical Dominance:

North America Leads the Fusion Biopsy Market with Advanced Healthcare Infrastructure

North America leads the Fusion Biopsy Market, propelled by advanced healthcare infrastructure, widespread acceptance of precision diagnostics, and increasing incidences of prostate cancer. The United States excels in robust research and development spending and advantageous reimbursement policies, facilitating industry growth. This supremacy draws international entities, promoting innovation and technical progress. As demand escalates, enterprises focusing on North America have a competitive advantage in revenue expansion.

Key Players

The “Global Fusion Biopsy Market” study report will provide a valuable insight with an emphasis on the global market.  The major players in the market are Eigen, Koninklijke Philips N.V., Hitachi Ltd., Focal Healthcare, MedCom, ESAOTE SPA, KOELIS, BK Medical Holding Company Inc., Biobot Surgical Pte Ltd, Exact Imaging, and UC-Care Medical Systems Ltd.

Fusion Biopsy Market Segment Analysis

Based on the research, Verified Market Research has segmented the market into Biopsy Route, Product, End User, and Geography.

Fusion Biopsy Market, by Biopsy RouteTransrectalTransperinealFusion Biopsy Market, by ProductEquipmentConsumablesFusion Biopsy Market, by End-UserHospitalsDiagnostic CentersAmbulatory Care CentersAcademic & Research LaboratoriesFusion Biopsy Market, by GeographyNorth AmericaU.SCanadaMexicoEuropeGermanyFranceU.KRest of EuropeAsia PacificChinaJapanIndiaRest of Asia PacificROWMiddle East & AfricaLatin America

Browse Related Reports:

Global Liquid Biopsy Market Size By Biomarker (Circulating Tumor Cells, Circulating Nucleic Acids), By Technology (NGS, PCR Microarrays), By Application (Cancer, Reproductive Health), End-User (Hospitals, Specialty Clinics), By Geography, And Forecast

Global Biopsy Devices Market Size By Product (Instruments For Needle-Based Biopsy, Biopsy Guidance Systems, Biopsy Needles (Disposable, Reusable), Biopsy Forceps), By End User (Hospitals & Clinics, Diagnostic Imaging Centres, Research Labs & Pharmaceutical Companies), By Application (Breast Biopsy, Bone Marrow Biopsy, Colorectal Biopsy, Lung Biopsies, Prostate Biopsies), By Geography, And Forecast

Global Plastic Surgery And Integumentary System Procedures Market Size By Procedure (Prefilled Syringe Biopsy, Excisional Biopsy), By Operating Area (Eyelids, Subcutaneous Tissue), By Application (Skin Grafts, Allograft), By End User (Hospitals And Clinics, Research Laboratories), By Geography, And Forecast

Global Biopsy Needles Market Size By Product Type (Biopsy Needles, Aspiration Needles), By Application (Tumor/Cancer Applications, Wound Applications), By Procedure (Image-guided Procedures, Non-image-guided Procedures), By End-User (Hospitals & Surgical Centers, Diagnostic Clinics & Pathology Laboratories, Ambulatory Care Centers, Research & Academic Institutes), By Geography, And Forecast

Top 7 Implantable Medical Device Companies advancing patient care

Visualize Fusion Biopsy Market using Verified Market Intelligence -:

Verified Market Intelligence is our BI Enabled Platform for narrative storytelling in this market. VMI offers in-depth forecasted trends and accurate Insights on over 20,000+ emerging & niche markets, helping you make critical revenue-impacting decisions for a brilliant future.

VMI provides a holistic overview and global competitive landscape with respect to Region, Country, Segment, and Key players of your market. Present your Market Report & findings with an inbuilt presentation feature saving over 70% of your time and resources for Investor, Sales & Marketing, R&D, and Product Development pitches. VMI enables data delivery In Excel and Interactive PDF formats with over 15+ Key Market Indicators for your market.

About Us

Verified Market Research® stands at the forefront as a global leader in Research and Consulting, offering unparalleled analytical research solutions that empower organizations with the insights needed for critical business decisions. Celebrating 10+ years of service, VMR has been instrumental in providing founders and companies with precise, up-to-date research data.

With a team of 500+ Analysts and subject matter experts, VMR leverages internationally recognized research methodologies for data collection and analyses, covering over 15,000 high impact and niche markets. This robust team ensures data integrity and offers insights that are both informative and actionable, tailored to the strategic needs of businesses across various industries.

VMR’s domain expertise is recognized across 14 key industries, including Semiconductor & Electronics, Healthcare & Pharmaceuticals, Energy, Technology, Automobiles, Defense, Mining, Manufacturing, Retail, and Agriculture & Food. In-depth market analysis cover over 52 countries, with advanced data collection methods and sophisticated research techniques being utilized. This approach allows for actionable insights to be furnished by seasoned analysts, equipping clients with the essential knowledge necessary for critical revenue decisions across these varied and vital industries.

Verified Market Research® is also a member of ESOMAR, an organization renowned for setting the benchmark in ethical and professional standards in market research. This affiliation highlights VMR’s dedication to conducting research with integrity and reliability, ensuring that the insights offered are not only valuable but also ethically sourced and respected worldwide.

Contact Us
Mr. Edwyne Fernandes
Verified Market Research®
US: +1 (650)-781-4080
US Toll Free: +1 (800)-782-1768
Email: sales@verifiedmarketresearch.com
Web: https://www.verifiedmarketresearch.com/
Follow Us: LinkedIn | Twitter | Threads | Instagram | Facebook

Logo: https://mma.prnewswire.com/media/2015407/VMR_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/fusion-biopsy-market-is-expected-to-generate-a-revenue-of-usd-1448-15-million-by-2032–globally-at-8-9-cagr-verified-market-research-302393044.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Purina Films Docuseries A Different Breed Earns Three Daytime Emmy® Award Nominations

Published

on

By

Emmy®-nominated series celebrates the extraordinary bond between people and pets through the world of canine competition

ST. LOUIS, July 21, 2026 /PRNewswire/ — When pet lovers see the human-pet bond in action, it creates connection and deepens the appreciation they have for the animals in their own lives. That connection recently led Purina to dive deeper into the world of canine competition through a docuseries that is now receiving critical acclaim. Today, Purina is celebrating three Daytime Emmy® Award nominations for A Different Breed, its original nine-episode documentary series produced through Purina Films in partnership with InkBlot Narratives and WPP Media, including recognition for Outstanding Lifestyle Program, Outstanding Editing and Outstanding Directing.

The Daytime Emmy® Awards recognize excellence in daytime television and streaming programming across lifestyle, documentary, instructional, travel, culinary and children’s content. A Different Breed is nominated alongside productions from some of the entertainment industry’s leading studios, networks and streaming platforms.

Streaming on Prime Video, A Different Breed follows 18 teams on the road to the Purina Pro Plan Incredible Dog Challenge National Finals, putting the spotlight on the competitors, their dogs and the extraordinary relationships that drive them. The series marks an intentional shift from traditional brand-led content toward storytelling that entertains, inspires and fosters meaningful connections – all in new channels and formats that resonate with the viewing habits of today’s consumer.

“The way people discover and engage with content continues to evolve, and we’re evolving with them,” said Andrea Faccio, President and Chief Growth Officer at Purina. “At Purina, we’ve always believed the bond between people and pets is full of inspiring stories. A Different Breed gave us the opportunity to share those stories in a way people actively choose to experience, and we’re incredibly proud to see them recognized alongside some of the industry’s most celebrated programs.”

Through Purina Films, Purina is evolving how it connects with pet lovers taking a more entertainment-led approach to storytelling, creating premium content that highlights the meaningful role pets play in people’s lives. By inviting viewers behind the scenes of the Purina Pro Plan Incredible Dog Challenge and into competitors’ lives and homes, A Different Breed tells the kinds of emotionally rich stories today’s audiences actively seek out.

The backdrop of the series is the Purina Pro Plan Incredible Dog Challenge, a premier canine performance sports competition that has showcased extraordinary canine athletes and their handlers for nearly 30 years. The competition features a variety of events, including high-flying disc routines, agility courses, weave pole racing and diving dog competitions.

The National Academy of Television Arts & Sciences will announce the winners of the Daytime Emmy Awards on October 30, 2026.

All nine episodes of A Different Breed are available to stream exclusively on Prime Video in the U.S. at no additional cost with a Prime membership. The second season of the Emmy®-nominated series is in production, continuing Purina’s commitment to bring audiences authentic stories that celebrate the incredible bond between people and pets.

About Nestlé Purina PetCare 
Nestlé Purina PetCare creates richer lives for pets and the people who love them. Founded in 1894, Purina has helped dogs and cats live longer, healthier lives by offering scientifically based nutritional innovations.

Purina manufactures some of the world’s most trusted and popular pet care products, including Dog Chow, Purina ONE, Pro Plan, Friskies and Tidy Cats. Our more than 11,000 U.S. associates take pride in our trusted pet food, treat and litter brands that feed 46 million dogs and 68 million cats every year. Nearly 500 Purina scientists, veterinarians, and pet care experts ensure our commitment to unsurpassed quality and nutrition.

Over the past five years, Purina has contributed more than $150 million towards organizations that bring, and keep, people and pets together, as well as those that help our communities and environment thrive.

Purina is part of Nestlé, a global leader in Nutrition, Health and Wellness. For more information, visit purina.com or subscribe here to get the latest Purina news.

View original content to download multimedia:https://www.prnewswire.com/news-releases/purina-films-docuseries-a-different-breed-earns-three-daytime-emmy-award-nominations-302831018.html

SOURCE Purina

Continue Reading

Technology

Toy Foundation Partners with Build-A-Bear & Chuck E. Cheese to Raise $100,000 for Children in Need

Published

on

By

The International Day of Play-themed cause marketing campaigns engaged consumers through promotions, exclusive product, & pin pad donations.

NEW YORK, July 21, 2026 /PRNewswire/ — The Toy Foundation™, the philanthropic arm of The Toy Association™, celebrated the United Nation’s International Day of Play (June 11) with two cause marketing campaigns with Build-A-Bear Foundation and Chuck E. Cheese. Together, the campaigns raised over $100,000, as families across the country and around the world supported The Toy Foundation’s mission to deliver the power of play to children in need.

The Toy Foundation’s partnership with Chuck E. Cheese included a three-part fundraising campaign throughout the month of June. At nearly 500 Chuck E. Cheese locations, families who donated $5 at checkout received 500 tickets to use toward prizes, turning a charitable gift into extra fun. Families also had the option to make a $1 or $3 donation directly at the pin pad, powered by FreedomPay’s Gateway to Giving™ — a charitable program that enables seamless giving at the point of sale, creating another opportunity to support a child in need. At select fun centers, families could also purchase a Chuck E. Cheese x Crazy Aaron’s Limited-Edition Thinking Putty, with one hundred percent of the purchase price benefitting The Toy Foundation.

“Partnering with The Toy Foundation this International Day of Play allowed us to make a real difference through the power of play,” said Scott Drake, CEO of CEC Entertainment. “Play is at the heart of everything we do, and we are deeply grateful to the families that joined us in supporting this great cause. Together, we are giving back in a meaningful way that inspires pride across our entire community.”

Build-A-Bear brought its signature warmth to workshops across the U.S. and the UK with a weeklong fundraising campaign held June 8 to 12. Shoppers made donations in amounts of their choosing at checkout, both in stores and online, with every dollar supporting The Toy Foundation’s work to deliver play to children in need.

“Build-A-Bear Foundation is proud to partner with The Toy Foundation in advancing the shared belief that play has the power to positively impact children’s lives,” said David Henderson, president of Build-A-Bear Foundation. “From toy donations and sponsorship support to this International Day of Play fundraising campaign, we are committed to helping create more moments of joy for children and families in need. We are so grateful to our guests and partners whose generosity continues to make that impact possible.”

These fundraising campaigns complimented The Toy Foundation’s International Day of Play toy collection initiative, which resulted in nearly 20 companies donating $5.7 million in toys. The toy donations are being distributed to more than 450,000 children in under-resourced communities, schools, and hospitals around the world.

“We are grateful to Build-A-Bear Foundation and Chuck E. Cheese for their support, collaboration, and partnership in hosting two successful cause marketing campaigns, and to the companies that generously donated toys in honor of International Day of Play,” said Pam Mastrota, executive director of The Toy Foundation. “Together, we are making a lasting impact, transforming children’s lives with the power of play.”

The Toy Foundation partners with companies and retailers to create tailored cause marketing campaigns that engage consumers and support children through play.

Campaign opportunities include:

Retail campaigns that donate a portion of proceeds from select productsPoint-of-sale donation campaignsCo-branded products featuring cause-related messagingCustomized campaigns tailored to a company’s goals

To learn more and get involved in advancing the toy industry’s collective impact, visit toyfoundation.org or contact The Toy Foundation team.

About The Toy Foundation™ www.toyfoundation.org
The Toy Foundation™ is a 501(c)(3) children’s charity and philanthropic arm of The Toy Association. The uniting force for the collective philanthropy of the toy industry, The Toy Foundation is dedicated to creating a world where every child experiences the comfort, joy, and extraordinary benefits of play. The Toy Foundation works toward this vision through two program areas, Toy Chest, a toy distribution initiative, and Play Fund, a grant distribution initiative. By working together, The Toy Foundation has delivered the power of play to 38 million children in need worldwide. To learn more about The Toy Foundation, visit toyfoundation.org.

About Build‑A‑Bear Workshop, Inc.
Founded in 1997, Build‑A‑Bear is a leading global retailtainment brand on a mission to add a little more heart to life. At Build-A-Bear, guests are invited to create personalized furry friends through a unique stuffing, dressing, accessorizing and naming process, accentuated by a memorable “heart ceremony” that creates moments of connection for people of all ages.

Over the years, Build‑A‑Bear has grown into a multi‑generational phenomenon, positioned at the intersection of pop‑culture trends. Beyond its signature retail experience, the brand also offers pre‑stuffed plush, gifting, partnerships with best‑in‑class licensed and collectible characters, and original storytelling through Build‑A‑Bear Entertainment, LLC. Build‑A‑Bear’s current brand platform and message, “The Stuff You Love,” crosses ages and cultures while celebrating nearly 30 years of helping people mark life’s meaningful moments.

Today, Build‑A‑Bear operates more than 650 company-owned, partner-operated and franchise experience locations across more than 30 countries, complemented by buildabear.com. Build‑A‑Bear Workshop, Inc. (NYSE: BBW) reported $529.8 million in total revenues for fiscal 2025, representing the company’s 5th consecutive year of record results. Learn more at the Investor Relations section of buildabear.com.

About Chuck E. Cheese
Chuck E. Cheese is where over 550,000 happy birthdays are celebrated every year. For nearly 50 years, Chuck E. Cheese has been the place Where A Kid Can Be A Kid®, making birthday kids the star of the show through its interactive experiences, arcade games and the beloved Chuck E. Cheese character. The brand operates more than 500 locations globally and remains committed to providing a fun, safe and inclusive environment through industry-leading programs such as Kid Check® and its partnership with Autism Speaks. As a strong advocate for local communities, Chuck E. Cheese has donated more than $24 million to schools and nonprofits through its fundraising programs. For more information, visit www.chuckecheese.com.

Contact: Erin Wright
The Toy Foundation
646.520.4851
ewright@toyfoundation.org

View original content:https://www.prnewswire.com/news-releases/toy-foundation-partners-with-build-a-bear–chuck-e-cheese-to-raise-100-000-for-children-in-need-302831086.html

SOURCE The Toy Foundation

Continue Reading

Technology

Play a Video Game Against a Dish of Living Neurons: Intactis Bio Launches “Biostack”

Published

on

By

Served from a rack mountable Biohybrid Processing Unit (BPU) to lower AI energy usage. 

SALT LAKE CITY, July 21, 2026 /PRNewswire/ — Intactis Bio launched the Biostack Alpha, a video game in which allows anyone to compete against living human neurons grown in the lab. A player sits on one side of the web-browser. On the other is Biohybrid Intelligence: a small population of neurons in a dish that receives the game board as patterns of electrical stimulation. These neurons then answer, move by move, where to drop the next piece.

 

Play a video game against living neurons in rack mountable Biohybrid Processing Unit (BPU) to lower AI energy usage.

Biocomputation is a field focused on curbing the AI energy crises by replacing inefficient silicon chips with low energy biological processors. Biostack is the most tactile and publicly accessible demonstration yet to emerge from the field of biocomputation. Play today at play.intactis.bio. 

A biocomputer you can rack

Biostack runs on the Intactis BPU (Biohybrid Processing Unit), a biocomputer built into the same form factor as the GPUs widely distributed in data centers today. Living neurons at its core are wrapped in the cooling, life support, and signal hardware needed to keep the neurons healthy while they compute. The unit pairs the living substrate with silicon and rack mountable networking, which allows the systems to scale out using existing data center infrastructure.

The map that makes neurons playable

What makes the tissue controllable is a computational neuroscience model. Intactis ran a comprehensive screen to map how electrical stimulus drives neural outputs, cataloguing more than 150 statistically significant relationships and accounting for up to 96% of the tissue’s response. “Biocomputation is not a black box. We have the actual equation,” said Daniel Rodriguez-Granrose, PhD, Founder and CEO of Intactis Bio. This design space lets the company map neural responses onto specific game controls, so the biocomputer can directly learn the Biostack board state and ideal responses in a closed loop.

How a dish of neurons plays

Each turn, Biostack compresses the board (the current piece, the height of every column, and any gaps) into a compact code and delivers it to the tissue as a timed sequence of electrical pulses. The neurons respond, and the system reads their answer as a six-bit placement: four bits choose one of ten columns, two bits choose one of four rotations. Together this represents over 1000 unique electrical inputs to encode the board space and up to 40 possible destinations for every piece. Intactis has successfully transmitted this information to the neurons, and mapped their response back to the live game. In this demo, game performance held and even improved across overnight gaps between sessions. The living network is genuinely shaped by use.

Why a game matters

The stakes reach well beyond the screen. AI’s appetite for electricity is on track to outrun global electricity production. A supercomputer can draw on the order of 20 megawatts; a human brain runs on about 20 watts. The company projects energy-cost reductions around 95%, total-cost reductions around 90%, and data center footprint reductions around 88% versus exaflop-scale silicon.

From demo to business

Intactis sells the capability as Cloud Biocompute as a Service, targeting gaming, robotics, AI and LLM developers already spending $20,000 or more per month on GPUs. The company has secured more than $1 million in early capital and non-dilutive support and is raising a $5 million seed round to bring the BPU to data center partners. Intactis is built by a team with more than $900 million in prior exits.

About Intactis Bio

Intactis Bio builds biohybrid computers that run living human neurons alongside silicon to deliver compute with dramatically lower energy, cost, and footprint. Its rack-mountable Biohybrid Processing Unit (BPU) targets the widening gap between AI compute demand and available power. Learn more at intactis.bio.

View original content to download multimedia:https://www.prnewswire.com/news-releases/play-a-video-game-against-a-dish-of-living-neurons-intactis-bio-launches-biostack-302831095.html

SOURCE Intactis Bio Corp

Continue Reading

Trending